399 related articles for article (PubMed ID: 32340819)
1. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
[TBL] [Abstract][Full Text] [Related]
2. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
3. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
4. Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study.
Prabhu A; Brandl A; Wakama S; Sako S; Ishibashi H; Mizumoto A; Takao N; Ichinose M; Motoi S; Liu Y; Yonemura Y
BJS Open; 2021 Mar; 5(2):. PubMed ID: 33839755
[TBL] [Abstract][Full Text] [Related]
5. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy in colorectal cancer.
Fisher OM; Brown C; Esquivel J; Larsen SG; Liauw W; Alzahrani NA; Morris DL; Kepenekian V; Sourrouille I; Dumont F; Tuech JJ; Ceribelli C; Doussot B; Sgarbura O; Alhosni M; Quenet F; Glehen O; Cashin PH;
BJS Open; 2024 May; 8(3):. PubMed ID: 38722737
[TBL] [Abstract][Full Text] [Related]
8. Effect of intraperitoneal chemotherapy concentration on morbidity and survival.
Elekonawo FMK; van Eden WJ; van der Plas WY; Ewalds RSG; de Jong LAW; Bremers AJA; Hemmer PHJ; Kok NFM; Kruijff S; Aalbers AGJ; de Reuver PR
BJS Open; 2020 Apr; 4(2):293-300. PubMed ID: 31950702
[TBL] [Abstract][Full Text] [Related]
9. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
10. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
[TBL] [Abstract][Full Text] [Related]
11. Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
Hulshof EC; Lurvink RJ; Caserta N; de Hingh IHJT; van Wezel T; Böhringer S; Swen JJ; Gelderblom H; Guchelaar HJ; Deenen MJ
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1925-1931. PubMed ID: 32354538
[TBL] [Abstract][Full Text] [Related]
12. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
[TBL] [Abstract][Full Text] [Related]
13. Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin.
Moaven O; Votanopoulos KI; Shen P; Mansfield P; Bartlett DL; Russell G; McQuellon R; Stewart JH; Levine EA
Ann Surg Oncol; 2020 Mar; 27(3):772-780. PubMed ID: 31720933
[TBL] [Abstract][Full Text] [Related]
14. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases.
Ljunggren M; Nordenvall C; Palmer G
Eur J Surg Oncol; 2021 Nov; 47(11):2865-2872. PubMed ID: 34116900
[TBL] [Abstract][Full Text] [Related]
15. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study.
Narasimhan V; Warrier S; Michael M; Ramsay R; Heriot A
J Gastrointest Surg; 2020 Sep; 24(9):2104-2112. PubMed ID: 31745907
[TBL] [Abstract][Full Text] [Related]
19. Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases: A Nationwide Population-Based Study.
van der Ven RGFM; van den Heuvel TBM; Rovers KPB; Nienhuijs SW; Boerma D; van Grevenstein WMU; Hemmer PHJ; Kok NFM; Madsen EVE; de Reuver P; Tuynman JB; van Erning FN; de Hingh IHJT
Ann Surg Oncol; 2024 Jun; 31(6):3758-3768. PubMed ID: 38453767
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk factors, treatment, and survival of ovarian metastases of colorectal origin: a Dutch population-based study.
Bakkers C; van der Meer R; Roumen RM; Lurvink RJ; Lemmens VE; van Erning FN; de Hingh IH
Int J Colorectal Dis; 2020 Jun; 35(6):1035-1044. PubMed ID: 32157379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
